Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1513/AnnalsATS.201511-778FR http://scihub22266oqcxt.onion/10.1513/AnnalsATS.201511-778FR C5461988!5461988 !27088424     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27088424 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Ann+Am+Thorac+Soc 2016 ; 13 (6 ): 933-44 Nephropedia Template TP {{tp|p=27088424 |t=2016. Pneumococcal Vaccination Strategies An Update and Perspective |pdf=|usr=}}{{27088424 }} gab.com Text Pneumococcal Vaccination Strategies An Update and Perspective JO: Ann Am Thorac Soc http://www.kidney.de/pget.php?&tw=1&pmid=27088424 #FOAvip Streptococcus pneumoniae is an important global pathogen that causes a wide range of clinical disease in children and adults. Pneumococcal pneumonia is by far the common presentation of noninvasive and invasive pneumococcal disease and affects the young, the elderly, and the immunocompromised disproportionately. Patients with chronic pulmonary diseases are also at higher risk for pneumococcal infections. Substantial progress over the century has been made in the understanding of pneumococcal immunobiology and the prevention of invasive pneumococcal disease through vaccination. Currently, two pneumococcal vaccines are available for individuals at risk of pneumococcal disease: the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal protein-conjugate vaccine (PCV13). The goal of pneumococcal vaccination is to stimulate effective antipneumococcal antibody and mucosal immunity response and immunological memory. Vaccination of infants and young children with pneumococcal conjugate vaccine has led to significant decrease in nasal carriage rates and pneumococcal disease in all age groups. Recent pneumococcal vaccine indication and schedule recommendations on the basis of age and risk factors are outlined in this Focused Review. As new pneumococcal vaccine recommendations are being followed, continued efforts are needed to address the vaccine efficacy in the waning immunity of the ever-aging population, the implementation of vaccines using two different vaccines under very specific schedules and their real world clinical and cost effectiveness, and the development of next generation pneumococcal vaccines. Twit Text FOAVip Pneumococcal Vaccination Strategies An Update and Perspective ????Ann Am Thorac Soc http://www.kidney.de/pget.php?&tw=1&pmid=27088424 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27088424 #FOAvip English Wikipedia <ref>{{Cite pmid|27088424 }}</ref> Pneumococcal Vaccination Strategies An Update and Perspective #MMPMID27088424 Berical AC ; Harris D ; Dela Cruz CS ; Possick JD Ann Am Thorac Soc 2016[Jun]; 13 (6 ): 933-44 PMID27088424 show ga Streptococcus pneumoniae is an important global pathogen that causes a wide range of clinical disease in children and adults. Pneumococcal pneumonia is by far the common presentation of noninvasive and invasive pneumococcal disease and affects the young, the elderly, and the immunocompromised disproportionately. Patients with chronic pulmonary diseases are also at higher risk for pneumococcal infections. Substantial progress over the century has been made in the understanding of pneumococcal immunobiology and the prevention of invasive pneumococcal disease through vaccination. Currently, two pneumococcal vaccines are available for individuals at risk of pneumococcal disease: the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal protein-conjugate vaccine (PCV13). The goal of pneumococcal vaccination is to stimulate effective antipneumococcal antibody and mucosal immunity response and immunological memory. Vaccination of infants and young children with pneumococcal conjugate vaccine has led to significant decrease in nasal carriage rates and pneumococcal disease in all age groups. Recent pneumococcal vaccine indication and schedule recommendations on the basis of age and risk factors are outlined in this Focused Review. As new pneumococcal vaccine recommendations are being followed, continued efforts are needed to address the vaccine efficacy in the waning immunity of the ever-aging population, the implementation of vaccines using two different vaccines under very specific schedules and their real world clinical and cost effectiveness, and the development of next generation pneumococcal vaccines. |Cost-Benefit Analysis [MESH] |Humans [MESH] |Immunity, Herd [MESH] |Immunization Schedule [MESH] |Pneumococcal Vaccines/*therapeutic use [MESH] |Pneumonia, Pneumococcal/epidemiology/*prevention & control [MESH] |Randomized Controlled Trials as Topic [MESH] |Risk Factors [MESH] |Streptococcus pneumoniae [MESH]Pneumococcal Vaccination Strategies An Update and Perspective (epmc).pdf DeepDyve Pubget Overpricing